Thalidomide neuropathy in patients treated for metastatic prostate cancer

Muscle and Nerve

Volumn 24, Issue 8, 2001, Pages 1050-1057

  Molloy, F M ^a   Floeter, M K ^a   Syed, N A ^a   Sandbrink, F ^a   Culcea, E ^a   Steinberg, S M ^b   Dahut, W ^b   Pluda, J ^b   Kruger, E A ^b   Reed, E ^b   Figg, W D ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Electromyography; Nerve conduction studies; Neuropathy; Thalidomide; Toxicity

Indexed keywords

THALIDOMIDE;

ADULT; AGED; AGING; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; ELECTRODIAGNOSIS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIAN NERVE; METASTASIS; MONITORING; NERVE CONDUCTION; NERVE POTENTIAL; NEUROLOGIC EXAMINATION; NEUROPATHY; PRIORITY JOURNAL; PROSTATE CANCER; RADIAL NERVE; SURAL NERVE; SYMPTOMATOLOGY; TREATMENT OUTCOME; ULNAR NERVE;

ACTION POTENTIALS; AGE FACTORS; AGED; AGED, 80 AND OVER; BRACHIAL PLEXUS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRODIAGNOSIS; ELECTROMYOGRAPHY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEURAL CONDUCTION; NEURONS, AFFERENT; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; SURAL NERVE; THALIDOMIDE;

EID: 0034947693     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/mus.1109     Document Type: Article

References (29)

1. 2′,3′-Dideoxycytidine (ddC) toxic neuropathy: A study of 52 patients
2. Prurigo nodularis and photosensitivity in AIDS: Treatment with thalidomide
3. Dose response, coasting, and differential fiber vulnerability, in human toxic neuropathy: A prospective study of pyridoxine neurotoxicity
4. Electrophysiological monitoring in clinical trials
5. Neuropathy after thalidomide ("Divastal")
6. Inter-and intra-examiner reliability, of nerve conduction measurements in normal subjects
7. Thalidomide neurotoxicity
8. A 4, 2, and 1 stepping algorithm for quick and accurate estimation of cutaneous sensation threshold
9. Human acetylation polymorphism
10. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen independent prostate cancer
11. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
12. Neuropathy after intake of thalidomide
13. Thalidomide neuropathy: A clinical electrophysiological, and histological follow-up study
14. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: Use of neurophysiological studies to detect thalidomide neuropathy
15. Thalidomide: Treatment of choice for aphthous ulcers in patients seropositive for human immunodeficiency virus
16. Polyneuropathy after neurosedyn (thalidomide) and its prognosis
17. Thalidomide-induced neuropathy and genetic differences in drug metabolism
18. Thalidomide-induced peripheral neuropathy. A prospective clinical, neurophysiological and pharmacogenetic evaluation
19. Thalidomide treatment of chronic discoid lupus erythematosus
20. Thalidomide neuropathy: An electrophysiologic study
21. The saga of thalidomide: Neuropathy to embryopathy, with case reports of congenital anomalies
22. The saga of thalidomide: Neuropathy to embryopathy, with case reports of congenital anomalies (concluded)
23. Clinical trials for polyneuropathy: The role of nerve conduction studies, quantitative sensory testing, and autonomic function testing
24. Guideline for the clinical use and dispensing of thalidomide
25. Thalidomide neuropathy: Role of F-wave monitoring
26. The treatment of lepta reaction in lepromatous leprosy: Fifteen years experience with thalidomide
27. Antitumor activity of thalidomide in refractory, multiple myeloma
28. Development of polyneuropathy during thalidomide therapy